Genmab A/S (GNMSF) Stock Price, News & Analysis

Company Overview

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing antibody-based medicines for cancer and other serious diseases. Founded in 1999, the company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system and target disease-related cells.

Genmab’s products include Darzalex (daratumumab), developed with Janssen Biotech for certain blood cancers; Epkinly (epcoritamab), developed with AbbVie for certain types of B-cell lymphoma; and Tivdak (tisotumab vedotin), developed with Seagen, now part of Pfizer, for recurrent or metastatic cervical cancer. Genmab also discovered the antibody underlying Kesimpta (ofatumumab), a Novartis treatment for multiple sclerosis. The company continues to advance a pipeline of proprietary and partnered antibody therapeutics.

Genmab serves international markets through its own research and development operations and collaborations with global pharmaceutical companies. Its activities extend across North America, Europe and Asia, with corporate and research operations in Denmark and the United States as well as additional international locations. Jan van de Winkel, a co-founder of Genmab, has served as the company’s chief executive officer since 2010.

Key Stats

• Today's Range: $329.25 to $329.25
• 50-Day Range: $274.50 to $338.00
• 52-Week Range: $232.34 to $352.00
• Volume: N/A
• Average Volume: 3,276 shs
• Market Capitalization: $20.27 billion
• P/E Ratio: 25.82
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Genmab A/S Stock Analysis - MarketRank™

Genmab A/S scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Genmab A/S.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Genmab A/S is 25.82, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.10.

Price to Earnings Ratio vs. Sector

The P/E ratio of Genmab A/S is 25.82, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.45.

Price to Book Value per Share Ratio

Genmab A/S has a P/B Ratio of 3.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.33% of the float of Genmab A/S has been sold short.

Short Interest Ratio / Days to Cover

Genmab A/S has a short interest ratio ("days to cover") of 23.95, which indicates bearish sentiment.

Change versus previous month

Short interest in Genmab A/S has recently decreased by 0.99%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genmab A/S does not currently pay a dividend.

Dividend Growth

Genmab A/S does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.58

News Sentiment

Genmab A/S has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Genmab A/S this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Genmab A/S insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.54% of the stock of Genmab A/S is held by insiders.

Percentage Held by Institutions

Genmab A/S has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 2/17/2026
• Today: 9/11/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:GNMSF
• CIK: 1434265
• Web: www.genmab.com
• Phone: (457) 020-2728
• Fax: 45-7020-2729
• Employees: 3,029
• Year Founded: 1999

Profitability

• EPS (Trailing Twelve Months): $12.75
• Trailing P/E Ratio: 25.82
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $963 million
• Net Margins: 19.08%
• Pretax Margin: 21.93%
• Return on Equity: 14.89%
• Return on Assets: 7.73%

Debt

• Debt-to-Equity Ratio: 0.81
• Current Ratio: 2.46
• Quick Ratio: 2.44

Sales & Book Value

• Annual Sales: $3.72 billion
• Price / Sales: 5.45
• Cash Flow: $15.65 per share
• Price / Cash Flow: 21.04
• Book Value: $88.49 per share
• Price / Book: 3.72

Miscellaneous

• Outstanding Shares: 61,570,000
• Free Float: 60,622,000
• Market Cap: $20.27 billion
• Optionable: Not Optionable
• Beta: 0.79